-
High-Content Screening of Schistosome Stem Cells
2026-09-21
Perera, Chioni, and Walker developed a quantitative high-content platform that measures neoblast proliferation in developmentally advanced liver-stage Schistosoma mansoni schistosomula. By combining fluorescence imaging, confocal microscopy, image segmentation, and a focused compound screen, the study identified prioritized anti-schistosomal candidates while providing a more informative phenotype than motility or gross morphology alone.
-
Type III Collagen Restricts Breast Cancer Progression
2026-09-21
The reference study identifies type III collagen as a tumor-restrictive component of the breast cancer microenvironment rather than merely a structural extracellular matrix protein. By combining patient tissue analysis, bioinformatics, 3D culture, fibroblast-derived matrices, and mouse models, it links higher Col3 relative to Col1 with less aggressive disease and provides a rationale for collagen-focused therapeutic strategies.
-
AZ 10417808 in ATRX-Deficient Glioma
2026-09-20
ATRX loss may create a therapeutically actionable vulnerability to receptor tyrosine kinase and PDGFR inhibition in high-grade glioma. This thought-leadership article translates the evidence into a practical framework for evaluating AZ 10417808, designing ATRX-stratified experiments, and prioritizing clinically relevant combination studies with temozolomide.
-
SW033291: Practical 15-PGDH Workflows
2026-09-19
SW033291 enables a staged path from recombinant-enzyme target engagement to prostaglandin E2 elevation, stem-cell responses, and regeneration-focused models. Its strongest use-case is comparative pathway research, including emerging muscle-repair studies during semaglutide-associated weight loss.
-
Type III Collagen Restricts Breast Cancer Progression
2026-09-18
The reference study identifies type III collagen (Col3) as a tumor-restrictive component of the breast cancer microenvironment rather than merely a structural ECM protein. By integrating fibroblast-derived matrices, patient tissue analysis, TCGA-BRCA bioinformatics, 3D culture, and mouse models, it links a higher Col3-to-type I collagen ratio with less aggressive disease and evaluates Col3 supplementation as a therapeutic concept.
-
Perospirone: Receptor and Kv1.5 Evidence
2026-09-18
Perospirone, also called SM-9018 free base, combines 5-HT2A and dopamine D2 receptor antagonism with 5-HT1A partial agonism. Recent electrophysiology evidence identifies concentration-dependent inhibition of vascular Kv channels, including a Kv1.5-linked component, creating a defined bridge between schizophrenia research and cardiovascular pharmacology.
-
LINC01977 Super-Enhancer Hijacking in Early LUAD
2026-09-17
Zhang et al. show that super-enhancer activation of the lncRNA LINC01977 reinforces canonical TGF-β/SMAD3 signaling and promotes early-stage lung adenocarcinoma malignancy. The study connects tumor-associated macrophage infiltration, chromatin accessibility, SMAD3 nuclear activity, and CBP/P300-dependent transcription, offering a mechanistic framework for lung adenocarcinoma research and epigenetics research.
-
SW033291: 15-PGDH Inhibition for Regeneration
2026-09-17
SW033291 connects biochemical 15-PGDH inhibition with prostaglandin E2 elevation, hematopoietic stem cell expansion, and tissue repair assays. This workflow-focused guide shows how to move from enzyme kinetics to marrow, muscle, and regeneration readouts while avoiding common dosing, solvent, and interpretation errors.
-
SW033291: 15-PGDH Inhibition in Regeneration
2026-09-16
SW033291 is a mechanistically defined 15-PGDH inhibitor for connecting prostaglandin E2 elevation with hematopoiesis, tissue repair, and emerging muscle-regeneration assays. This workflow-focused guide shows how to move from enzyme kinetics to cellular validation while avoiding common solvent, timing, and endpoint errors.
-
APEX-RNA-MS Maps RNA Modifications in Cells
2026-09-16
Seo, Dhingani, and Kleiner introduce APEX-RNA-MS, a workflow that combines APEX2 proximity labeling with nucleoside LC-MS to profile modified RNAs near defined protein neighborhoods. The study links m6A and m5C to DNA damage foci and shows that cytosolic tRNAs accumulate with G3BP1 in arsenite-induced stress granules, providing a route to study RNA chemistry in structures that are difficult to isolate intact.
-
Allosteric PDK4 Inhibitors for Metabolic Disease
2026-09-15
Lee and colleagues identified compound 8c as a potent allosteric pyruvate dehydrogenase kinase 4 inhibitor with an in vitro IC50 of 84 nM. Its metabolic, glucose-tolerance, allergy, and cancer-related data establish a useful preclinical framework for developing PDK4-directed therapies while leaving important questions about selectivity, exposure, and clinical translation.
-
ARCA Cy3 EGFP mRNA (5-moUTP) Guide
2026-09-15
ARCA Cy3 EGFP mRNA (5-moUTP) combines Cy3-based RNA tracking, EGFP reporter gene expression, an ARCA cap, and 5-methoxyuridine modified mRNA chemistry. Its dual fluorescence design supports direct assessment of mRNA localization and translated protein output in mammalian cell workflows.
-
Staurosporine: Kinase Signaling Workflow Guide
2026-09-14
Use Staurosporine as a calibrated apoptosis inducer, pathway-dissection tool, and perturbation control rather than as a selective kinase probe. This workflow connects concentration, timing, orthogonal readouts, and troubleshooting to cancer research while carefully translating insights from a glutathione-and-cataract study.
-
Tunable Human Intestinal Organoids for Self-Renewal
2026-09-14
Yang and colleagues developed a human small intestinal organoid system that combines sustained stem-cell self-renewal with broad, controllable differentiation under a single culture condition. The study shows that stemness enhancement can increase lineage diversity, while BET, Wnt, Notch, and BMP pathway modulation provides reversible or directional control over intestinal cell fate.
-
Cediranib (AZD2171) In Vitro Workflow
2026-09-13
Build more interpretable angiogenesis and cancer research assays with Cediranib, an ATP-competitive VEGFR inhibitor that links pathway suppression to functional endothelial responses. This workflow separates reduced proliferation from true cell death while providing practical dosing, storage, validation, and troubleshooting guidance.